Literature DB >> 36273058

The Long-Term Outcome of Laparoscopic Resection for Perihilar Cholangiocarcinoma Compared with the Open Approach: A Real-World Multicentric Analysis.

Tingting Qin1, Min Wang1, Hang Zhang1, Jingdong Li2, Xiaxing Deng3, Yuhua Zhang4, Wenxing Zhao5, Ying Fan6, Dewei Li7, Xuemin Chen8, Yechen Feng1, Siwei Zhu9, Zhongqiang Xing10, Guangsheng Yu11, Jian Xu2, Junjie Xie3, Changwei Dou4, Hongqin Ma5, Gangshan Liu6, Yue Shao7, Weibo Chen8, Simiao Xu12, Jun Liu13, Jianhua Liu14, Xinmin Yin15, Renyi Qin16.   

Abstract

OBJECTIVE: The aim of this study was to compare the short- and long-term outcomes of laparoscopic surgery (LS) and open surgery (OP) for perihilar cholangiocarcinoma (PHC) using a large real-world dataset in China.
METHODS: Data of patients with PHC who underwent LS and OP from January 2013 to October 2018, across 10 centers in China, were extracted from medical records. A comparative analysis was performed before and after propensity score matching (PSM) in the LS and OP groups and within the study subgroups. The Cox proportional hazards mixed-effects model was applied to estimate the risk factors for mortality, with center and year of operation as random effects.
RESULTS: A total of 467 patients with PHC were included, of whom 161 underwent LS and 306 underwent OP. Postoperative morbidity, such as hemorrhage, biliary fistula, abdominal abscess, and hepatic insufficiency, was similar between the LS and OP groups. The median overall survival (OS) was longer in the LS group than in the OP group (NA vs. 22 months; hazard ratio [HR] 1.19, 95% confidence interval [CI] 1.02-1.39, p = 0.024). Among the matched datasets, OS was comparable between the LS and OP groups (NA vs. 35 months; HR 0.99, 95% CI 0.77-1.26, p = 0.915). The mixed-effect model identified that the surgical method was not associated with long-term outcomes and that LS and OP provided similar oncological outcomes.
CONCLUSIONS: Considering the comparable long-term prognosis and short-term outcomes of LS and OP, LS could be a technically feasible surgical method for PHC patients with all Bismuth-Corlett types of PHC.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36273058     DOI: 10.1245/s10434-022-12647-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  50 in total

1.  Surgical strategy for hilar cholangiocarcinoma of the left-side predominance: current role of left trisectionectomy.

Authors:  Isamu Hosokawa; Hiroaki Shimizu; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideyuki Yoshitomi; Masaru Miyazaki
Journal:  Ann Surg       Date:  2014-06       Impact factor: 12.969

2.  Extended resections for hilar cholangiocarcinoma.

Authors:  P Neuhaus; S Jonas; W O Bechstein; R Lohmann; C Radke; N Kling; C Wex; H Lobeck; R Hintze
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 3.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

Review 4.  Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma.

Authors:  Rungsun Rerknimitr; Phonthep Angsuwatcharakon; Thawee Ratanachu-ek; Christopher J L Khor; Ryan Ponnudurai; Jong Ho Moon; Dong Wan Seo; Linda Pantongrag-Brown; Apichat Sangchan; Pises Pisespongsa; Thawatchai Akaraviputh; Nageshwar D Reddy; Amit Maydeo; Takao Itoi; Nonthalee Pausawasdi; Sundeep Punamiya; Siriboon Attasaranya; Benedict Devereaux; Mohan Ramchandani; Khean-Lee Goh
Journal:  J Gastroenterol Hepatol       Date:  2013-04       Impact factor: 4.029

5.  Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma.

Authors:  Mee Joo Kang; Jin-Young Jang; Jihoon Chang; Yong Chan Shin; Dooho Lee; Hong Beom Kim; Sun-Whe Kim
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

6.  Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.

Authors:  Cecilia G Ethun; Alexandra G Lopez-Aguiar; Douglas J Anderson; Andrew B Adams; Ryan C Fields; Maria B Doyle; William C Chapman; Bradley A Krasnick; Sharon M Weber; Joshua D Mezrich; Ahmed Salem; Timothy M Pawlik; George Poultsides; Thuy B Tran; Kamran Idrees; Chelsea A Isom; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Kenneth Cardona; Shishir K Maithel
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

Review 7.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

8.  Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.

Authors:  Bas Groot Koerkamp; Jimme K Wiggers; Peter J Allen; Marc G Besselink; Leslie H Blumgart; Olivier R C Busch; Robert J Coelen; Michael I D'Angelica; Ronald P DeMatteo; Dirk J Gouma; T Peter Kingham; William R Jarnagin; Thomas M van Gulik
Journal:  J Am Coll Surg       Date:  2015-09-15       Impact factor: 6.113

Review 9.  Current Management of Perihilar Cholangiocarcinoma and Future Perspectives.

Authors:  Heather L Lewis; Amir A Rahnemai-Azar; Mary Dillhoff; Carl R Schmidt; Timothy M Pawlik
Journal:  Chirurgia (Bucur)       Date:  2017 May-Jun

10.  Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.

Authors:  Ji Won Park; Sung-Bum Kang; Jie Hao; Seok-Byung Lim; Hyo Seong Choi; Duck-Woo Kim; Hee Jin Chang; Dae Yong Kim; Kyung Hae Jung; Tae-You Kim; Gyeong Hoon Kang; Eui Kyu Chie; Sun Young Kim; Dae Kyung Sohn; Jae-Sung Kim; Hye Seung Lee; Jee Hyun Kim; Seung-Yong Jeong; Jae Hwan Oh
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.